ArticleArchives of endocrinology and metabolism2026
Changes of serum fibroblast growth factor 23 (FGF23) and Klotho in diabetic kidney disease and their correlation with coronary artery calcification: a retrospective study.
Article in Archives of endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study investigated the association among fibroblast growth factor 23 (FGF23), Klotho, and coronary artery calcification (CAC) in patients with diabetic kidney disease (DKD). SUBJECTS AND
methodsA total of 176 DKD patients and 160 age-and diabetes-matched controls were retrospectively analyzed. We measured serum FGF23 and Klotho levels by enzyme-linked immunosorbent assay and assessed CAC by CAC scoring. Correlation and receiver operating characteristic analyses were performed to evaluate the associations of these biomarkers with CAC and their ability to discriminate CAC.
resultsFGF23 levels were significantly higher and Klotho levels were lower in patients with DKD than in controls. FGF23 correlated negatively with estimated glomerular filtration rate and positively with the albumin-to-creatinine ratio and blood urea nitrogen, whereas Klotho correlated positively with estimated glomerular filtration rate and negatively with albumin-to-creatinine ratio and blood urea nitrogen. In patients with CAC, FGF23 levels were higher and Klotho levels were lower. Receiver operating characteristic analysis showed that both FGF23 and Klotho discriminated CAC, and FGF23 showed a higher area under curve than Klotho. Correlation analysis further confirmed the association of FGF23 and Klotho with CAC severity.
conclusionFGF23 and Klotho were associated with renal impairment and CAC in patients with DKD and may serve as potential biomarkers of renal and cardiovascular risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.